EE47 Cost-Effectiveness of Abiraterone, Enzalutamide, and Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (MCSPC): A Partitioned-Survival Model
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.353
https://www.valueinhealthjournal.com/article/S1098-3015(23)00453-9/fulltext
Title :
EE47 Cost-Effectiveness of Abiraterone, Enzalutamide, and Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (MCSPC): A Partitioned-Survival Model
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00453-9&doi=10.1016/j.jval.2023.03.353
First page :
Section Title :
Open access? :
No
Section Order :
11741